

CURRICULUM VITAE

NAME:

Mark Sanchez, M.D.

DATE AND PLACE OF BIRTH:

March 25, 1969, Indianapolis, IN

BUSINESS ADDRESS/PHONE:

Edward Zbella, MD, PA
DBA: Florida Fertility Institute

2454 McMullen Booth Road, Suite 601
Clearwater, FL 33759
(727) 796-7705

3268 66th Street N
St. Petersburg, FL 33710
(727) 341-1991

7171 North Dale Mabry, Suite 405
Tampa, FL 33614
(813) 933-9166

Women's Medical Research Group
2454 McMullen Booth Road, Suite 609
Clearwater, FL 33759
(727) 724-9730

HEALTH:

Excellent

EDUCATION:

UNDERGRADUATE:

Seminole Community College
Sanford, Florida
1/1988-5/1989
Degree: A.A., Biology

University of South Florida
Tampa, Florida
5/1989-4/1991
Degree: B.S., Biology

GRADUATE:

University of Florida College of Medicine
Gainesville, Florida
8/1991-5/1995
Degree: Doctorate of Medicine

Internship in Obstetrics and Gynecology

Bayfront Medical Center
St. Petersburg, Florida
7/1995-6/1996

Resident in Obstetrics and Gynecology
Bayfront Medical Center
St. Petersburg, Florida
7/1996-6/1999

Fellowship in Reproductive Endocrinology
University of South Florida
Tampa, Florida
7/99-6/2002

MEDICAL LICENSE:

Florida 71673

SPECIALTY BOARD, AWARDS AND HONORS:

Board Certified,
Reproductive Endocrinology and Infertility
2005

Board Certified, American Board of
Obstetrics and Gynecology
2004

Board Eligible
Reproductive Endocrinology and Infertility
6/2002

Honors Convocation
University of South Florida
1990

Minority Affairs Dean's Scholarship
University of Florida College of Medicine
1993

Outstanding Leadership
University of Florida College of Medicine
1994

Resident Research Award for outstanding research
In endometriosis, Bayfront Medical Center
1998

Organon Resident Research Award, Outstanding
Research in Women's Health
1999

The American Association of Gynecologic
Laparoscopists, Excellence in Endoscopic
Procedures
1999

The American Society for Colposcopy and Cervical
Pathology, Excellence in Colposcopy and the
Treatment of Lower Genital Tract Disease Award
1999

American Heart Association, Florida Puerto Rico
Postdoctoral Grant recipient. July 2001. Grant
entitled:

Regulation of the High Density Lipoprotein
Receptor by
Estradiol
2001

Bayfront Medical Center Obstetrics and
Gynecology
Attending of the Year July 2000 through June 2001
2001

MEMBERSHIPS:

Fellow
American College of Obstetrics and Gynecology
2004

Member,
American Society for Colposcopy and Cervical
Pathology
1999

Member,
American Association of Gynecologic
Laparoscopists
1999

Associate Member,
Society for Reproductive Endocrinology and
Infertility
1999

Associate Member,
American Society for Reproductive Medicine
1999

PROFESSIONAL APPOINTMENTS:

Process Improvement Team

Bayfront Medical Center
1997-1999

Quality Assurance Committee
Bayfront Medical Center
1997-1999

Chief Administrative Resident
Bayfront Medical Center
1998-1999

Resident Selection Committee
Bayfront Medical Center
1998-1999

Medical Education Committee
Bayfront Medical Center
1995-1999

Library Committee
Bayfront Medical Center
1995-1999

Residency Selection Committee
Bayfront Medical Center
1998-1999

Residency Selection Committee
University of South Florida, Dept. OB/GYN
1999-2002

Peer Review Committee
University of South Florida, Dept. OB/GYN
2001-2002

Reproductive Endocrinologist
Florida Fertility Institute, Suite 601
Clearwater, Florida 2002-present

Women's Medical Research Group, Suite 605
Associate Medical Director
Clearwater, Florida 2003-present

**RESEARCH, PUBLICATIONS,
AND PRESENTATIONS:**

1. Incidence of Multiple Gestations in Patients with Endometriosis Undergoing IVF.

2. Tuboovarian Abscess after Saline Sonohysterography.
3. Ectopic Pregnancy in a Retained Fallopian Tube after Hemihysterectomy.
4. A Clinicopathologic Study Comparing AJCC Staging in Breast Cancer Patients.
5. Diabetic Retinopathy: An Interpretation of A,B, and C Waves in Streptozotosin Induced Diabetic Rats.
6. Saline Infusion Sonography and Your Practice; Midwinter's Conference, February 2000.
7. Effects of Dax-1 and Alien on Star promoter (In progress).
8. Genetic Regulation of the HDL-R Promoter by Estradiol, Abstract: Society for Gynecologic Investigation, Toronto 2001.
9. Estrogen Enhances the High Density Lipoprotein Receptor Through Four Estrogen Response Elements, Submitted: Endocrinology.
10. Dax-1 Represses the High Density Lipoprotein Receptor Through Interaction with Positive Regulators Sterol Regulatory Element Binding Protein-1a and Steriodogenic Factor-1, Submitted: Endocrinology.
11. University Fertility Associates website development, www.universityfertilityassociates.com

CLINICAL RESEARCH STUDIES

1. **STUDY TITLE:** A phase II, 6 month, randomized, double-blind study to evaluate the efficacy and safety of three doses of J867 versus placebo in subjects with endometriosis.
PROTOCOL: M01-398
COMPLETION YEAR: 2004
SPONSOR: TAP Laboratories
SUBINVESTIGATOR: Mark Sanchez, M.D.
2. **STUDY TITLE:** A phase II, 3 month, randomized, double-blind study to evaluate the efficacy and safety of two doses of J867 versus placebo in subjects with uterine leiomyomata.
PROTOCOL: M02-408, Extension of M01-398
COMPLETION YEAR: 2005
SPONSOR: TAP Laboratories

- SUBINVESTIGATOR:** Mark Sanchez, M.D.
3. **STUDY TITLE:** A phase III, 12 month, randomized, double-blind study to evaluate the efficacy and safety of three doses of J867 versus placebo in subjects with uterine leiomyomata.
- PROTOCOL:** M01-390
COMPLETION YEAR: 2004
SPONSOR: TAP Laboratories
SUBINVESTIGATOR: Mark Sanchez, M.D.
4. **STUDY TITLE:** A phase III, 12 month, randomized, double-blind study to evaluate the efficacy and safety of three doses of J867 versus placebo in subjects with uterine leiomyomata.
- PROTOCOL:** M01-391, extension of M01-390
COMPLETION YEAR: 2005
SPONSOR: TAP Laboratories
SUBINVESTIGATOR: Mark Sanchez, M.D.
5. **STUDY TITLE:** An Open Label Study of the Contraceptive Efficacy and Safety OF Triphasic Norethindrone acetate 1 mg / Ethinyl Estradiol 0.005, 0.030, and 0.035 mg Oral Tablets Administered for 24 Days of a 28-day Cycle.
- PROTOCOL:** PR 10503
COMPLETION YEAR: 2005
SPONSOR: Warner Chilcott
SUBINVESTIGATOR: Mark Sanchez, M.D.
6. **STUDY TITLE:** A Phase III, Continuation Study to Evaluate the Safety of Asoprisinil Beyond 2 years in Subjects with Uterine Leiomyomata.
- PROTOCOL:** A-FB04-078
COMPLETION YEAR: 2006
SPONSOR: TAP
SUBINVESTIGATOR: Mark Sanchez, M.D.
7. **STUDY TITLE:** A safety and efficacy study of N, O-Carboxymethylchitosan (NOCC) when used for reduction of postoperative adhesion development In women undergoing laparoscopy.
- PROTOCOL:** Chito-03
COMPLETION YEAR: 2004
SPONSOR: Chitogenics, Inc.
SUBINVESTIGATOR: Mark Sanchez, M.D.
8. **STUDY TITLE:** The Efficacy of Eszopiclone 3 mg Compared to Placebo in the treatment of Insomnia Secondary to Perimenopause or Menopause.
- PROTOCOL:** 190-054

- COMPLETION YEAR:** 2005
SPONSOR: Sepracor
SUBINVESTIGATOR: Mark Sanchez, M.D.
9. **STUDY TITLE:** Evaluation of safety and efficacy of Prometrium capsules in induction of secretory conversion of endometrium and WITHDRAWAL bleeding in subjects with secondary amenorrhea.
PROTOCOL: S1684002
COMPLETION YEAR: 2008
SPONSOR: Solvay Pharmaceuticals, Inc
SUBINVESTIGATOR: Mark Sanchez, M.D.
10. **STUDY TITLE:** Efficacy Study Comparing 0.9 g and 1.25 g EstroGel 0.03% Doses with Placebo in the treatment of Vasomotor Symptoms and Vulvar and Vaginal Atrophy Associated with Menopause.
PROTOCOL: S1664003
COMPLETION YEAR: 2005
SPONSOR: Solvay
SUBINVESTIGATOR: Mark Sanchez, M.D.
11. **STUDY TITLE:** A multi-center, double-phase, randomized, Double blind, placebo controlled study evaluating the effect of Tolterodine ER on urgency urinary incontinence, urgency, frequency, sexual quality of life and sexual function in women with overactive bladder.
PROTOCOL: A6121002
COMPLETION YEAR: 2006
SPONSOR: Pfizer
SUBINVESTIGATOR: Mark Sanchez, M.D.
12. **STUDY TITLE:** A multi-center, randomized, open-label, parallel group study of vaginal micronized progesterone tablet (Endometrium) compared to Crinone 8% vaginal gel in female patients undergoing in-vitro fertilization (IVF).
PROTOCOL: 2004-02 (IVF)
COMPLETION YEAR: 2006
SPONSOR: Ferring Pharmaceutical
SUBINVESTIGATOR: Mark Sanchez, M.D.
13. **STUDY TITLE:** A multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of three dosage strengths of Pulsatile GnRH administered intravenously or subcutaneously via portable infusion pump compared to oral treatment with Clomiphene

Citrate in anovulatory or oligoovulatory infertile females.

PROTOCOL: Pulsatile GnRH 2004-05 (IV Pump)
COMPLETION YEAR: 2006
SPONSOR: Ferring Pharmaceuticals
SUBINVESTIGATOR: Mark Sanchez, M.D.

14. STUDY TITLE: Randomized, double-blind, double-dummy, parallel group, multi-center study to compare the efficacy and safety of once-monthly oral administration of 150 mg ibandronate with once-weekly oral administration of 70 mg alendronate in postmenopausal osteoporosis-non-inferiority trial.

PROTOCOL: MM 17385
COMPLETION YEAR: 2006
SPONSOR: Roche
SUBINVESTIGATOR: Mark Sanchez, M.D.

15. STUDY TITLE: A multi-center, double-blind, placebo-controlled comparison of multiple doses of esterified estrogens and methyltestosterone, in combination and alone, in relieving vasomotor symptoms on postmenopausal women.

PROTOCOL: SO202112
COMPLETION YEAR: 2007
SPONSOR: Solvay Pharmaceuticals
SUBINVESTIGATOR: Mark Sanchez, M.D.

16. STUDY TITLE: A randomized, double-blind, placebo-controlled, parallel-group study comparing Clindamycin Phosphate 2% Butoconazole Nitrate 2% combination vaginal cream with Clindesse, Gynazole-1, and placebo.

PROTOCOL: KV05-601-622467
COMPLETION YEAR: 2006
SPONSOR: KV Pharmaceutical Co.
SUBINVESTIGATOR: Mark Sanchez, M.D.

17. STUDY TITLE: A double-blind randomized, placebo-controlled dose-ranging study of the effects of ERB-041 in the reduction of symptoms associated with endometriosis in reproductive aged women.

PROTOCOL: 3142A2-200-US
COMPLETION YEAR: 2006
SPONSOR: Wyeth
SUBINVESTIGATOR: Mark Sanchez, M.D.

18. STUDY TITLE: A phase II, randomized, double-blind, placebo-controlled study of NBI-56418 in endometriosis.

PROTOCOL: NBI-56418-0501

- COMPLETION YEAR:** 2006
SPONSOR: Neurocrine Biosciences
SUBINVESTIGATOR: Mark Sanchez, M.D.
- 20. STUDY TITLE:** A phase II, randomized, double-blind, placebo-controlled twice-daily dosing study of NBI-56418 in endometriosis.
PROTOCOL: NBI-56418-0504
COMPLETION YEAR: 2007
SPONSOR: Neurocrine Biosciences
SUBINVESTIGATOR: Mark Sanchez, M.D.
- 21. STUDY TITLE:** A double-blind, randomized, placebo-controlled, efficacy and safety study of bazeoxifene/conjugated estrogens combinations for treatment of vasomotor symptoms associated with menopause.
PROTOCOL: 3115A1-305-US
COMPLETION YEAR: 2007
SPONSOR: Wyeth
SUBINVESTIGATOR: Mark Sanchez, M.D.
- 22. STUDY TITLE:** A double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of 75 MG and 150 MG doses of ERB-041 on the reduction of symptoms associated with endometriosis during treatment and post treatment in reproductive-aged women.
PROTOCOL: 3142A2-203-WW
COMPLETION YEAR: 2007
SPONSOR: Wyeth
SUBINVESTIGATOR: Mark Sanchez, M.D.
- 23. STUDY TITLE:** A randomized, placebo-controlled phase II study of multiple dosing regimens of intravaginally administered 851B Gel for the treatment of cervical high risk HPV infection.
PROTOCOL: 1547-851B
COMPLETION YEAR: 2008
SPONSOR: Takeda
SUBINVESTIGATOR: Mark Sanchez, M.D.
- 24. STUDY TITLE:** A phase II, multicenter, double-blind, randomized, placebo-controlled study to evaluate two doses of a Danazol vaginal ring for the management of moderate to severe endometriosis-related non-menstrual pelvic pain.
PROTOCOL: DR-DZL-201
COMPLETION YEAR: 2007
SPONSOR: Duramed
SUBINVESTIGATOR: Mark Sanchez, M.D.

25. **STUDY TITLE:** A phase II, prospective, randomized, double-blind, multi-center, dose finding, comparative study for the evaluation of the aromatase inhibitor anastrozole (Multiple-Dose) versus Clomiphene Citrate in stimulating follicular growth and ovulation in infertile women with ovulatory dysfunction.
- PROTOCOL:** 25550
COMPLETION YEAR: Ongoing
SPONSOR: Serono
SUBINVESTIGATOR: Mark Sanchez, M.D
26. **STUDY TITLE:** A phase IV, multi-center, randomized, double-blind, clinical trial to confirm the efficacy of the 75 IU dose of Luveris vs. placebo when administered with follitropin alfa for induction of follicular development and pregnancy in hypogonadotropic hypogonadal women with profound LH deficiency, as defined by a baseline LH level <1.2 IU/L.
- PROTOCOL:** 26109
COMPLETION YEAR: Ongoing
SPONSOR: Serono
SUBINVESTIGATOR: Mark Sanchez, M.D
27. **STUDY TITLE:** A randomized, multi-center, double-blind, placebo-controlled trial to compare the effects of 12 weeks of treatment with DR-2041 vaginal cream vs. placebo vaginal cream on vulvovaginal atrophy in healthy postmenopausal women.
- PROTOCOL:** DR-CEN-302
COMPLETION YEAR: 2007
SPONSOR: Duramed
SUBINVESTIGATOR: Mark Sanchez, M.D
28. **STUDY TITLE:** A multi-center validation study of the daily log of sexual activities (DLSA) in postmenopausal women.
- PROTOCOL:** S0302108
COMPLETION YEAR: 2007
SPONSOR: Solvay Pharmaceuticals, Inc.
SUBINVESTIGATOR: Mark Sanchez, M.D
29. **STUDY TITLE:** A multi-center, randomized, double-blind study to compare the efficacy and safety of patient-initiated Famciclovir 1000 mg B.I.D. X 1 day to Valacyclovir 500 mg B.I.D. X 3 days in immunocompetent adults with recurrent genital herpes.

PROTOCOL: CFAM810A2308
COMPLETION YEAR: 2006
SPONSOR: Novartis
SUBINVESTIGATOR: Mark Sanchez, M.D

30. STUDY TITLE: A twelve-week randomized, double-blind, placebo-controlled, parallel group, forced titration, proof of concept study to assess the efficacy, safety and tolerability as well as the pharmacokinetic profile of 60 mg and 120 mg of GW679769 administered once daily vs. placebo in women with overactive bladder.

PROTOCOL: NKB105022
COMPLETION YEAR: 2006
SPONSOR: GlaxoSmithKline
SUBINVESTIGATOR: Mark Sanchez, M.D.

31. STUDY TITLE: A multi-center, double-blind, randomized, parallel-group, placebo-controlled, 7 cycle duration (196 days), phase 3 study of oral Estradiol Valerate/Dienogest tablets for the treatment of dysfunctional uterine bleeding.

PROTOCOL: DUB 308960
COMPLETION YEAR: 2008
SPONSOR: Quintiles
SUBINVESTIGATOR: Mark Sanchez, M.D.

32. STUDY TITLE: A Phase II, Randomized, Double-Blind, Active Controlled Study to Assess the Safety and efficacy of NBI-56418 in Subjects with Endometriosis.

PROTOCOL: NBI-56418-0603
COMPLETION YEAR: Ongoing
SPONSOR: Neurocrine
SUBINVESTIGATOR: Mark Sanchez, M.D.

33. STUDY TITLE: A multi-center, randomized, double-blind phase III study of the efficacy and safety of the Misoprostol vaginal insert (MVI) compared to Cervidil for women requiring cervical ripening and induction of labor.

PROTOCOL: Miso-Obs-004
COMPLETION YEAR: 2007
SPONSOR: Cytokine PharmaSciences, Inc
PRINCIPLE INVESTIGATOR: Mark Sanchez, M.D.

34. STUDY TITLE: A phase II clinical study evaluating the safety and efficacy of two regimens of Danazol administered intravaginally for three months in women with moderate-to-severe pain associated with endometriosis

PROTOCOL: DZ2-201-601-725036
COMPLETION YEAR: Ongoing
SPONSOR: KV Pharmaceutical
SUBINVESTIGATOR: Mark Sanchez, M.D.

35. **STUDY TITLE:** A phase IIIb, randomized, open, multi-center study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV-16/18 LI/AS04 vaccine co-administered intramuscularly with GlaxoSmithKline Biologicals Boostrix vaccine and/or Sanofi-Aventis' Menactra vaccine according to different dose schedule combinations as compared to the administered of HPV vaccine, Boostrix or Menactra alone in healthy female subjects aged 11-18 years.

PROTOCOL: 107682 (HPV-018)
COMPLETION YEAR: Ongoing
SPONSOR: GlaxoSmithKline
SUBINVESTIGATOR: Mark Sanchez, M.D.

36. **STUDY TITLE:** A double-blind, randomized, controlled study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals' herpes simplex candidate vaccine (gD2-AS04) in healthy HSV seronegative and seropositive female subjects aged 10-17 years.

PROTOCOL: 208141/040
COMPLETION YEAR: 2008
SPONSOR: GlaxoSmithKline Biologicals
SUBINVESTIGATOR: Mark Sanchez, M.D.

37. **STUDY TITLE:** A phase III, multi-center, randomized, double-blind, placebo-controlled study of IoGen for the treatment of moderate or severe, periodic breast pain associated with symptomatic fibrocystic breast disease in otherwise healthy, euthyroid, pre-menopausal women.

PROTOCOL: SYM-CL-005
COMPLETION YEAR: 2007
SPONSOR: Symbollon Pharmaceuticals, Inc
SUBINVESTIGATOR: Mark Sanchez, M.D.

38. **STUDY TITLE:** A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multi-Center Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the treatment of Nocturia in Adults.

PROTOCOL: FE992026
COMPLETION YEAR: 2007
SPONSOR: Ferring
SUBINVESTIGATOR: Mark Sanchez, M.D.

- 39. STUDY TITLE:** A Phase II, 18-week, Double-blind, Placebo-Controlled, Multi-center Study Evaluating the Safety and Efficacy of Lidocaine/Diphenhydramine Combination Cream in the treatment of Vulvar Vestibulitis Syndrome.
- PROTOCOL:** LDC-201-601-669020
COMPLETION YEAR: 2009
SPONSOR: KV Pharmaceuticals
SUBINVESTIGATOR: Mark Sanchez, M.D.
- 40. STUDY TITLE:** Randomized, Double-blind, Parallel-Group Study Evaluating the Safety and Efficacy of of Clindamycin/Butoconazole Vaginal Cream in the treatment of mixed Bacterial Vaginosis/Vulvovaginal Candiadiasis Infections.
- PROTOCOL:** CBC-302-602-622467
COMPLETION YEAR: 2009
SPONSOR: KV Pharmaceuticals
SUBINVESTIGATOR: Mark Sanchez, M.D.
- 41. STUDY TITLE:** A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled Study to evaluate the effects of SCE-B on Nocturnal Vasomotor Symptoms in Postmenopausal Women.
- PROTOCOL:** DR-ENJ-401
COMPLETION YEAR: Ongoing
SPONSOR: Duramed Research
SUBINVESTIGATOR: Mark Sanchez, M.D.
- 42. STUDY TITLE:** A Phase III, Single-Blind, Randomized Study to Compare DR-2011 to a Progesterone Vaginal Gel for luteal Phase Supplementation for InVitro Fertilization.
- PROTOCOL:** DR-PGN-302
COMPLETION YEAR: Ongoing
SPONSOR: Duramed Research
PRINCIPLE INVESTIGATOR: Mark Sanchez, M.D.
- 43. STUDY TITLE:** A double-blind, Randomized, Multicenter Study to Investigate the Endometrial Safety of a Continuous, Combined, Oral Estrogen/Progestin Preparation (0.5 mg 17 β -estradiol [E2] / 0.25 mg drospirenone [DRSP]) and to Compare the Bleeding Pattern of Subjects treated with 1.0 mg E2 / .5 mg norethisterone acetate (NETA) when used for hormone therapy (HT) for 1 year in Post-Menopausal Women.
- PROTOCOL:** 310523
COMPLETION YEAR: Ongoing
SPONSOR: Bayer

- SUBINVESTIGATOR:** Mark Sanchez, M.D.
- 44. STUDY TITLE:** A Randomized, Double-blind, Placebo-Controlled, Multi-center, 52-Week Study to Evaluate the Endometrial Safety of Transdermal Testosterone (300mcg/day) in Naturally Post-Menopausal Women with Hypoactive Sexual Desire Disorder.
- PROTOCOL:** 2007004
COMPLETION YEAR: 2009
SPONSOR: Proctor and Gamble
SUBINVESTIGATOR: Mark Sanchez, M.D.
- 45. STUDY TITLE:** A Phase II, Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and SAFETY OF nbi-56418 in Subjects with Endometriosis.
- PROTOCOL:** NBI-56418-0702
COMPLETION YEAR: Ongoing
SPONSOR: Neurocrine Biosciences
SUBINVESTIGATOR: Mark Sanchez, M.D.
- 46. STUDY TITLE:** A multi-center Extension Study Investigating the Long Term Efficacy and Safety of a Fast-Dissolving (“Melt”) Formulation of Desmopressin for the treatment of Nocturia in Adults.
- PROTOCOL:** FE992026 CS31
COMPLETION YEAR: Ongoing
SPONSOR: Ferring Pharmaceuticals
SUBINVESTIGATOR: Mark Sanchez, M.D.
- 47. STUDY TITLE:** A multi-center, Open-Label, Single-Arm Study to assess the Efficacy and Safety of the Oral Contraceptive SH TOO186D (0.02 mg ethinyl estradiol as betaex clathrate and 3 mg drospirenone) in a flexible extended regimen in 1356 healthy females for 1 Year.
- PROTOCOL:** 311642
COMPLETION YEAR: Ongoing
SPONSOR: Bayer
SUBINVESTIGATOR: Mark Sanchez, M.D.
- 48. STUDY TITLE:** A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator to evaluate efficacy and safety of ssr240600C in women with overactive bladder including urge urinary incontinence.
- PROTOCOL:** DR16271
COMPLETION YEAR: 2008
SPONSOR: Sanofi-Aventis
SUBINVESTIGATOR: Mark Sanchez, M.D.

- 49. STUDY TITLE:** A multi-center, Randomized, Controlled Study to Investigate the Safety and Tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care Testing Iron Deficiency Anemia in Heavy Uterine Bleeding and Postpartum Patients.
- PROTOCOL:** IVIT07017
COMPLETION YEAR: 2009
SPONSOR: Luitpold
SUBINVESTIGATOR: Mark Sanchez, M.D.
- 50. STUDY TITLE:** A multicenter, randomized, double-blind, active-controlled, parallel group, 2-arm study to show superiority of the oral contraceptive SH T00658ID over Ortho Tri-Cyclen Lo on hormone withdrawal associated symptoms after 6 cycles of treatment.
- PROTOCOL:** 13108
COMPLETION YEAR: Ongoing
SPONSOR: Bayer
SUBINVESTIGATOR: Mark Sanchez, M.D.
- 51. STUDY TITLE:** A Double blind, Randomized, Placebo-Controlled Study assessing the safety and efficacy of DVS SR for the treatment of Vasomotor symptoms associated with menopause.
- PROTOCOL:** 3151A2-3353-NA
COMPLETION YEAR: Ongoing
SPONSOR: Wyeth
SUBINVESTIGATOR: Mark Sanchez, M.D.